OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	¥20.00	+5.26%	194,553,200
02/07/26	¥19.00	0.00%	181,453,800
01/07/26	¥19.00	+5.56%	173,643,500
30/06/26	¥18.00	0.00%	179,754,900
29/06/26	¥18.00	-5.26%	147,011,300

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed Japan Exchange Other stock markets 09:30:00 03/07/2026 +03			5-day change	1st Jan Change
20.00 ^JPY	+5.26%		+5.26%	-

24/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI

Market Cap	8.06B 50.07M 43.75M 40.18M 37.47M 71.03M 4.77B 72.23M 484M 187M 2.34B 188M 184M	P/E 2024	-3.3x	P/E 2025	-8.97x
Enterprise Value	7.22B 44.9M 39.23M 36.02M 33.59M 63.69M 4.27B 64.76M 434M 168M 2.1B 169M 165M	EV / Sales 2024	6.27x	EV / Sales 2025	9.03x
Free-Float	88.29%	Yield 2024 *	-	Yield 2025	-

24/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI
10/04/25	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding	CI
29/04/24	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
22/04/24	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI
05/04/24	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	CI
18/09/23	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	CI
12/05/23	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
10/04/23	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	CI
24/03/23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	CI
28/04/21	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
12/04/21	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
15/01/19	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	CI

14/05/24	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
05/12/23	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
13/09/22	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer	PU
01/10/20	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine	AQ

OncoTherapy Science, Inc. Stock

Stocks

4564

JP3202150003

Biotechnology & Medical Research

Valuation: OncoTherapy Science, Inc.

Chart: OncoTherapy Science, Inc.

Latest news : OncoTherapy Science, Inc.

Press Releases: OncoTherapy Science, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: OncoTherapy Science, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	+5.26%
1 week	+5.26%
Current month	+11.11%
3 months	-16.67%
6 months	-4.76%

1 week	18	20
1 month	18	21
Current year	18	34
1 year	18	34
3 years	15	64
5 years	15	111
10 years	15	338

Manager	Title	Age	Since
Junichi Shimada PSD	President	65	01/07/2022
Zehyon Paku PSD	President	50	05/12/2019
Yuka Yamane CTO	Chief Tech/Sci/R&D Officer	53	01/08/2012

Director	Title	Age	Since
Yuichi Komine BRD	Director/Board Member	54	01/09/2014
Zehyon Paku BRD	Director/Board Member	50	01/06/2018
Hatsuo Kato CHM	Chairman	82	01/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOTHERAPY SCIENCE, INC.	+5.26%	+5.26%	-25.93%	-50.00%	45.3M
ARGENX SE	-0.56%	+4.54%	+78.11%	+134.69%	58.73B
WUXI APPTEC CO., LTD.	-3.12%	+3.48%	+72.79%	+94.67%	53.92B
BIONTECH SE	+3.86%	+8.38%	-9.90%	-9.62%	24.67B
INSMED INCORPORATED	+4.30%	+6.82%	+13.60%	+428.91%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.68%	+13.56%	+45.43%	-1.52%	18.8B
GENMAB A/S	-0.39%	+9.64%	+44.43%	-28.04%	17.61B
PHARMAESSENTIA CORPORATION	+2.57%	+16.74%	+171.12%	+355.99%	16.25B
EXELIXIS, INC.	+3.50%	+4.92%	+26.07%	+192.26%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.39%	+17.75%	+40.87%	-	13.9B
Average	+2.52%	+7.97%	+45.66%	+124.15%	24.22B
Weighted average by Cap.	+0.98%	+7.21%	+57.60%	+136.31%

	2024	2025
Net sales	610M 3.79M 3.31M 3.04M 2.84M 5.38M 361M 5.47M 36.63M 14.19M 177M 14.24M 13.93M	750M 4.66M 4.07M 3.74M 3.49M 6.61M 444M 6.72M 45.03M 17.45M 218M 17.5M 17.12M
Net income	-1.29B -8.01M -6.99M -6.42M -5.99M -11.36M -762M -11.55M -77.34M -29.97M -374M -30.06M -29.4M	-815M -5.07M -4.43M -4.06M -3.79M -7.19M -482M -7.31M -48.94M -18.97M -237M -19.02M -18.61M
Net Debt	-527M -3.28M -2.86M -2.63M -2.45M -4.65M -312M -4.72M -31.64M -12.26M -153M -12.3M -12.03M	-833M -5.18M -4.52M -4.15M -3.87M -7.34M -493M -7.47M -50.02M -19.38M -242M -19.44M -19.02M